Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease
Authors
Keywords
-
Journal
Journal of Parkinsons Disease
Volume 9, Issue 1, Pages 157-171
Publisher
IOS Press
Online
2019-02-06
DOI
10.3233/jpd-181503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Semaglutide: First Global Approval
- (2018) Sohita Dhillon DRUGS
- Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
- (2018) Maka S Hedrington et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
- (2018) Liping Zhang et al. NEUROPEPTIDES
- Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease
- (2018) Peng Feng et al. NEUROPHARMACOLOGY
- Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
- (2018) Christian Hölscher NEUROPHARMACOLOGY
- A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease
- (2017) Ziyue Yuan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
- (2017) Yanwei Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease
- (2017) Jaishree Jalewa et al. NEUROPHARMACOLOGY
- Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells
- (2017) Theodora Panagaki et al. Scientific Reports
- Impaired autophagy activity is linked to elevated ER-stress and inflammation in aging adipose tissue
- (2016) Amiya Kumar Ghosh et al. Aging-US
- Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function
- (2016) Dong-Kyu Kim et al. Autophagy
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System
- (2016) B.-W. Kim et al. JOURNAL OF NEUROSCIENCE
- Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
- (2016) Patrick P. Michel et al. NEURON
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- A53T Human -Synuclein Overexpression in Transgenic Mice Induces Pervasive Mitochondria Macroautophagy Defects Preceding Dopamine Neuron Degeneration
- (2015) L. Chen et al. JOURNAL OF NEUROSCIENCE
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Inflammation is genetically implicated in Parkinson’s disease
- (2015) N. Dzamko et al. NEUROSCIENCE
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Cell Death Signaling
- (2015) Douglas R. Green et al. Cold Spring Harbor Perspectives in Biology
- Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
- (2014) Christian Hölscher BIOCHEMICAL SOCIETY TRANSACTIONS
- Inflammation-sleep interface in brain disease: TNF, insulin, orexin
- (2014) Ian A Clark et al. Journal of Neuroinflammation
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence
- (2013) Jessica Freiherr et al. CNS DRUGS
- Gut hormones as therapeutic agents in treatment of diabetes and obesity
- (2013) Tricia Tan et al. CURRENT OPINION IN PHARMACOLOGY
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- The current and projected economic burden of Parkinson's disease in the United States
- (2013) Stacey L. Kowal et al. MOVEMENT DISORDERS
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Autophagy and apoptosis dysfunction in neurodegenerative disorders
- (2013) Saeid Ghavami et al. PROGRESS IN NEUROBIOLOGY
- Programmed Cell Death in Parkinson's Disease
- (2013) K. Venderova et al. Cold Spring Harbor Perspectives in Medicine
- Alpha-synuclein’s degradation in vivo
- (2012) Darius Ebrahimi-Fakhari et al. Autophagy
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
- (2012) Kelvin C. Luk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases
- (2012) Mahesh Ramalingam et al. JOURNAL OF NEURAL TRANSMISSION
- The many faces of α-synuclein: from structure and toxicity to therapeutic target
- (2012) Hilal A. Lashuel et al. NATURE REVIEWS NEUROSCIENCE
- The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease
- (2012) Caitriona M. Long-Smith et al. NEUROMOLECULAR MEDICINE
- In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease
- (2012) S. Iannaccone et al. PARKINSONISM & RELATED DISORDERS
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- Mitochondria and Programmed Cell Death in Parkinson's Disease: Apoptosis and Beyond
- (2011) Celine Perier et al. ANTIOXIDANTS & REDOX SIGNALING
- The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease
- (2011) Rui D. S. Prediger et al. CURRENT PHARMACEUTICAL DESIGN
- Insulin resistance impairs nigrostriatal dopamine function
- (2011) J.K. Morris et al. EXPERIMENTAL NEUROLOGY
- Lixisenatide for type 2 diabetes mellitus
- (2011) Mikkel Christensen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death
- (2011) Laura A. Volpicelli-Daley et al. NEURON
- The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1
- (2010) Masaaki Komatsu et al. NATURE CELL BIOLOGY
- Mechanisms of mitophagy
- (2010) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease
- (2010) T. Tokuda et al. NEUROLOGY
- Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
- (2009) Xiaomin Su et al. HUMAN GENE THERAPY
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Absolute requirement of GDNF for adult catecholaminergic neuron survival
- (2008) Alberto Pascual et al. NATURE NEUROSCIENCE
- Association between AKT1 gene and Parkinson's disease: A protective haplotype
- (2008) Georgia Xiromerisiou et al. NEUROSCIENCE LETTERS
- Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
- (2008) Claire Henchcliffe et al. Nature clinical practice. Neurology
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started